Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Bexsero in Korean Adolescents
NCT01973218Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2013
- Primary completion
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease (2 arms), sponsored by Novartis. Primary endpoint: Percentage of Subjects With Serum Bactericidal Antibody (SBA) Titers >= 1:4 Against Neisseria Meningitidis Serogroup B at Day 61. Started Nov 2013; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT01973218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01973218.